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A heterogeneous human immunodeﬁciency virus-like particle
(VLP) formulation produced by a novel vector system
Joshua Pankrac1, Katja Klein1,2, Paul F. McKay 3, Deborah F. L. King3, Katie Bain1, Jason Knapp1, Tsigereda Biru2,
Chanuka N. Wijewardhana1, Rahul Pawa1, David H. Canaday2, Yong Gao1,2, Sarah Fidler4, Robin J. Shattock3, Eric J. Arts1,2 and
Jamie F. S. Mann1,2
First identiﬁed as the etiological agent behind Acquired Immunodeﬁciency Syndrome (AIDS) in the early 1980s, HIV-1 has continued
to spread into a global pandemic and major public health concern. Despite the success of antiretroviral therapy at reducing HIV-1
viremia and preventing the dramatic CD4+ T-cell collapse, infected individuals remain HIV positive for life. Unfortunately, it is
increasingly clear that natural immunity is not, and may never be, protective against this pathogen. Therefore, efﬁcacious vaccine
interventions, which can either prevent infection or eradicate the latent viral reservoir and effect cure, are a major medical priority.
Here we describe the development of a safe vaccine platform, currently being utilized in on-going prophylactic and therapeutic
preclinical studies and consisting of highly heterogeneous virus-like particle formulations that represent the virus diversity within
infected individuals. These VLPs contain no 5′LTR, no functional integrase, and have a severely mutated stem loop 1—thereby
preventing any potential reverse transcription, integration, and RNA packaging. Furthermore, we demonstrate that these VLPs are
morphologically identical to wild-type virus with polyvalent Env in a functional form. Finally, we show that the VLPs are antigenic
and capable of generating strong immune recall responses.
npj Vaccines  (2018) 3:2 ; doi:10.1038/s41541-017-0040-6
INTRODUCTION
Since its identiﬁcation as the etiological agent behind Acquired
Immunodeﬁciency Syndrome (AIDS), human immunodeﬁciency
virus type 1 (HIV-1) has become a global pandemic and major
public health concern. Despite the success of antiretroviral
therapy (ART) at reducing viral loads and preventing CD4+ T-cell
loss, infection endures owing to the establishment of a
transcriptionally silent latent reservoir in CD4+ T cells.1 As natural
immunity is not protective against HIV-1, the development of an
effective vaccine strategy remains the best countermeasure to the
advancing pandemic.
Despite a lack of natural immunity against HIV-1 infection and
few correlates of protection to guide vaccine development, it is
anticipated anti-HIV-1 vaccines should elicit potent cellular and
humoral immune responses. Apart from the modest protection
observed in the RV144 trial, HIV vaccines have failed to induce any
protective efﬁcacy in clinical trials.2,3 Accordingly, there is a
renewed focus on therapeutic HIV vaccine development and the
elimination of cell-associated or cell-free HIV in patients treated
with ART. Thus it is a priority to develop improved vaccine
immunogens that can activate both cellular and humoral immune
responses with a view to not only protect against HIV acquisition
but also to eliminate viral reservoirs such that viral remission or
even a cure is achieved. A signiﬁcant impediment to vaccine
efﬁcacy is thought to be the sheer HIV-1 sequence diversity.4 A
preventative vaccine must protect against HIV strains/subtypes
circulating in multiple geographic regions, while therapeutic
vaccines must elicit an immune response that overcomes the
high intra-patient sequence diversity and any immune escape
mutations. Polyvalent Env vaccines are one approach designed to
overcome the viral diversity and involves the use of heterologous
HIV-1 Env mixtures to expose developing immune responses to
diverse Env conformations.5–8 Nonetheless, a monovalent,
let alone polyvalent, native Env structure is difﬁcult to achieve
outside of the HIV particle. Polyvalent Env vaccines may provide
vaccine breadth and harness the elusive neutralizing antibody
response, which has both therapeutic and preventative beneﬁts.9–
11 This does not discount that non-neutralizing antibodies may
play a vital role in vaccine-mediated protection.12 From another
standpoint, eliciting broad cellular immune responses through
vaccination is also highly desirable considering cytotoxic T
lymphocyte (CTL) responses can reduce viral loads, thereby
contributing to the elimination of productively infected cells.13
In pursuit of more efﬁcacious HIV vaccines, efforts have focused
on virus-like particles (VLPs), due to their capability of presenting
native Env spikes on their surfaces, as well as their capacity to be
endocytosed and presented to T cells in the context of both major
histocompatibility complex class I and II.14 VLPs are deﬁned as viral
particles (VPs) that have undergone protein and lipid self-
assembly to generate non-infectious VPs devoid of any viral
genetic material. Furthermore, VLPs may be morphologically
indistinguishable from wild-type infectious virus and present the
entire HIV proteome as antigen. Currently, there are four licensed
VLP-based prophylactic vaccines providing protective immunity
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against inﬂuenza, Hepatitis B, and Human Papilloma virus
infection.14
Herein we describe a safe, chimeric HIV-1 VLP vector system,
capable of accommodating near full-length HIV genomes and
captures the HIV diversity present within patient samples. The
vector system was designed to generate VLPs for testing as anti-
HIV therapeutic and prophylactic vaccine purposes.15 Viral RNA
from plasma of HIV-infected volunteers was reverse transcribed
and cloned into a DNA vector for yeast-based recombination/gap
repair. Full-length patient-derived HIV-1 genomes were mutated
during the cloning process to stop reverse transcription, integrase
(IN) activity, and genomic RNA packaging into VLPs. The VLPs
express the processed HIV-1 proteome, were morphologically
indistinguishable from HIV VPs, and were capable of stimulating
both CD4 T cell and cytotoxic responses in heterologous patient
samples. Finally, the VLPs were combined to form a highly diverse
vaccine formulation called Heterologous Clade B Activating-Vector
(Het_B_ACT-VEC), which shared the phenotypic and antigenic
properties of the aforementioned VLPs.
RESULTS
Yeast-based gap/repair recombination to clone full-length HIV
genomes from patients
Here we describe the ease of full genome cloning to produce
patient-derived VP (containing the viral genome) and VLPs
(lacking the viral genome), the latter of which is currently being
tested as a therapeutic vaccine (JFS Mann, manuscript submitted).
In addition, we will describe the representative sampling of the
HIV population from plasma of infected patients into DNA vectors
used to produce the vaccine constructs. Ultimately, the VP of
different patients can be combined to generate heterogenous,
near full-length, multivalent vaccines for both therapeutic (as part
of amfAR preclinical studies) and preventative modalities (as part
of the European HIV Vaccine Initiative).
A total of ﬁve HIV+ plasmas from infected volunteers, diagnosed
at chronic stage of infection, were used to generate our vaccines.
Samples from chronic disease were chosen to clone VP prepara-
tions as they exhibit extensive diversity compared to acute
samples or transmitted/founder clones and therefore may provide
better vaccine breadth. Following reverse transcription (RT), we
used external-nested PCR to amplify the full genome of HIV in two
halves, overlapping by 113 bp within IN. These overlapping 5′ and
3′ patient-speciﬁc HIV-1 DNA fragments were transfected into
Saccharomyces cerevisiae along with linearized pREC-nﬂΔgenome/
URA3. Following a double recombination event in yeast, all
resulting colonies were harvested to acquire maximum viral
diversity—a process well described in multiple articles16–18 (Fig.
S1). The DNAs were then transfected into 293T cells to produce
VPs. As shown in Fig. 1a–c, we detected signiﬁcant levels of HIV-1
capsid p24 and RT activity in the cell-free supernatants with each
of the pREC-nﬂ plasmids containing the genomes of the patient-
derived HIV (VP1, VP2, VP3, VP4, and VP5).
We also assessed and veriﬁed the presence of p24 and RT
activity in 293T cells transfected with pREC-nﬂ plasmids (Fig. 1a, b).
Env expression was conﬁrmed using a viral tropism (Veritrop)
assay (Fig. 1c). The Veritrop assay was done by transfecting
293T cells with the pREC-nﬂ plasmids and mixing the cells with
CD4+/CCR5+ U87 cells, which harbor the pDM128FLUC plasmid as
previously described.19 Here cell fusion and light emission occurs
when 293T cells express functional HIV-1 gp120/gp41 Env, Rev,
and Tat from the pREC-nﬂ vectors. Env binds CD4+/CCR5+ and
mediates 293T/U87 cell fusion, permitting luciferase protein
expression. All VP and VLP pREC-nﬂ vectors had similar levels of
light emission, indicative of similar levels of Env, Rev, and Tat.
Genetic diversity of patient-derived HIV-1 genomes with the pREC
nﬂ vector
The sheer genetic quasi-species of HIV-1 present within infected
individuals, owing to a combination of low-ﬁdelity RT activity and
genetic recombination, is a signiﬁcant obstacle in the pursuit of
viable prophylactic and therapeutic HIV vaccines. Thus a success-
ful vaccine might need to be sufﬁciently “rich in diversity” to have
adequate protective coverage. Several vaccine studies have
evaluated heterologous, polyvalent, and sequential vaccine
strategies to promote B-cell afﬁnity maturation and enhanced
antibody production. Yeast-based recombination/gap repair is a
highly efﬁcient cloning technique and can yield hundreds of yeast
colonies carrying pREC clones with HIV genomes. To determine
the relative genetic bottlenecks in the cloning strategy, we RT-PCR
or PCR ampliﬁed the C2-V3 env fragment from the patient plasma,
from the recombined and puriﬁed pREC-nﬂ vector, and from the
gRNA contained in the VLPs. These env PCR products were then
subjected to next-generation sequencing (NGS) and analyzed
using the methods described previously.20 Similar topologies in
maximum likelihood phylogenetic trees, similar genetic distances,
and similar numbers of unique clones (>1% of the total sequence
reads) for the plasma, plasmid, and WT Env population were seen
from each patient sample (Fig. 2 and Table S2).
Reducing genomic RNA packaging and inactivating IN
Full genome ampliﬁcations of the ﬁve patients were repeated but
using primer sets to disrupt the gRNA packaging signal and/or the
IN active site (Fig. S1). The 5′ primer of fragment 1 contained
either 9 point mutations in stem loop 1 (698C>T, 718C>G, 719G>T,
720G>C, 721C>G, 722AT, 723A>T, 724G>C, and 731G>A, herein
designated dS.1) or a 33 bp deletion within stem loop 3
(nucleotides 755–787, herein designated ΔSL3) as described
previously by Clever and Parslow.21 This work was initially carried
out to identify the minimal gRNA packaging element of HIV-1
using HXB2 pseudotyped with amphotropic murine leukemia
virus. However, in our system it was necessary to conﬁrm that
these mutations would reduce gRNA encapsidation in our patient-
derived VLP. Thus our VLPs would be inherently safer vaccine
constructs compared to our VP formulations. Initially, the dS.1
mutation and ΔSL3 deletion were introduced into the pREC-nﬂNL4-
3 and used to transfect 293T cells (Fig. S2a, c, e). Resulting particles
were harvested and puriﬁed from cell-free supernatants and
found to have 142- and 11.6-fold less gRNA with the dS.1 and
ΔSL3 mutations, compared to NL4-3-VPs. This work was further
veriﬁed using HIV-1 clade C Env 1086 (Fig. S2b, d, f). We then
mutated the patient-derived viruses, VP3, VP4, and VP5 and again
found that the dS.1 mutations impaired gRNA packaging more so
than the ΔSL3 mutations (Fig. 3a and Fig. S3c).
With evidence that dS.1 reduced gRNA packaging in primary
vaccine particles, we proceeded to introduce both the dS.1
mutation and the RRK>AAH IN mutations via primer-related
replacement during PCR ampliﬁcation of the 5′/upstream genome
half and the IN mutations into the 3′/downstream half of the
genome. The two overlapping PCR products representing the
halves of the genome with these mutations were then cloned into
our pREC vector by yeast recombination/gap repair as described
above. Following plasmid puriﬁcation and particle production
from transfected 293T cells, we tested these dS.1/mutIN-mutated
VLPs for CAp24/Gag content by enzyme-linked immunosorbent
assay (ELISA) and western blot, encapsidated gRNA by real-time
RT-PCR, endogenous RT activity using exogenous poly(rA)oligo(dT)
template, or the endogenous gRNA template (Fig. 1), and ﬁnally,
IN activity by using VLPs soaked in lysis buffer containing
radiolabeled substrates for dinucleotide cleavage by IN (data not
shown). The addition of the RRK>AAH IN mutations, removal of
the 5′ long terminal repeat (LTR), and introduction of the dS.1
mutations did not impact Gag/CAp24 levels or RT activity on an
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exogenous template in the VLP preparations. However, none of
these mutated VLPs had dinucleotide cleavage activity/end
processing as mediated by functional IN, as observed and
compared with wild-type HIV particles (data not shown).
Finally, we repeated the cell-to-cell fusion assay by transfecting
293T cells with the pREC-nﬂ vectors harboring the mutations with
the patient-derived sequencing. Evidence of wild-type cell fusion
suggest that Env is expressed from pREC and can bind to CD4+/
CCR5+ on the U87 cells. Western blots show the presence of Env in
cell-free supernatant (data not shown). Previous studies using a
Vpr-blam construct expressed in trans and encapsidated into
VLPs22 clearly show VLP entry into CD4+/CCD5+ cells and that the
levels of VLP entry correlated with the levels of cell-to-cell fusion
mediated by pREC-nﬂ (used to produce the same VLP).
Vaccine VP and VLP are phenotypically identical to wild-type virus
As described above, the dS.1/mutIN VLPs and wild-type VPs
contained similar amounts of Gag and Env proteins and similar
levels of RT activity. However, the dS.1/mutIN VLPs lacked IN
activity, HIV-1 gRNA, and the ability to initiate and reverse
transcribe (–) strand strong stop DNA. However, the general
morphology of the VLPs compared to wild-type HIV is unknown.
Fig. 1 Viral particle (VP) and virus-like particle (VLP) formulations express similar vial protein concentrations. a, d pREC_nﬂ VP (red) and
pREC_nﬂ_dS.1/mutIN VLP (blue) DNA constructs were used to transiently transfect 293T cells in 24-well tissue culture plates for 48 h. After 48
h, culture supernatants were assessed for viral p24 production using a p24 ELISA Kit. Results shown represent mean p24 values (+/− SEM). b, e
Culture supernatants were also harvested to asses VP and VLP reverse transcriptase activity in counts per minute (CPM) using an in-house
radioactive RT assay. c, f To demonstrate the presence and functionality of HIV Env on VP and VLP, an HIV-1 co-receptor tropism assay was
used. The 293T cells were transfected with the VP and VLP pREC-nﬂ plasmids and mixed with CD4+/CCR5+ U87 cells harboring the
pDM128FLUC plasmid. Cell fusion elicits luciferase expression if the 293T cells express functional HIV-1 gp120/gp41 Env glycoproteins, Rev,
and Tat from the pREC-nﬂ vectors. Results are represented by mean relative light units (RLU) (+/−SEM) with background luminescence
subtracted from positive and negative results
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Thus we performed transmission electron microscopy (TEM) on
293T cells transfected with our pREC_nﬂ constructs. All VPs and
dS.1/mutIN VLP pREC-nﬂ DNAs produced vesicular structures
around the cells with some appearing to bud from the cell surface
(Fig. 4a). These circular structures contained electron-dense
membrane layers and were ~100 nm in diameter, akin to HIV
particles. Tetherin is constitutively expressed in restrictive human
cells and cell lines such as HeLa, H9, Jurkat, Molt4, primary T cells,
and primary macrophages.23 As Tetherin activity is absent in the
293T producer cell line, we did not expect nor did we observe any
VPs or VLPs “tethering” on the surface of transfected cells.
However, since the full HIV-1 proteome is produced by transfec-
tion with pREC_nﬂ DNAs, we suspect that HIV-1 Vpu is produced
and should downregulate/degrade of BST2/Tetherin24—support-
ing the use of the pREC-nﬂ as DNA vaccine vectors. As the VPs and
VLPs were imaged while budding or shortly after budding from
cell membranes, these particles are immature and therefore the
absence of noticeable capsid within the particles was expected. As
p24 and protease cleaved p17 (Figs. 1 and 4c) are readily detected
in all preparations, we would expect an electron-dense capsid to
form in mature VPs and VLPs.
The size of the puriﬁed VP and VLP was veriﬁed by dynamic
light scattering (DLS). DLS depends upon Brownian motion and
any resulting photon interference/deﬂection in liquid systems can
be used to determine particle size and polydispersity. Following
puriﬁcation, the VP and VLPs had an average diameter centered
around 100 nm (Fig. 4b), which agreed with the prior TEM
measurements.
Genetic diversity in the VPs and VLPs
Our previously formulated VP pREC-nﬂ derived from patient
samples were compared to PCR ampliﬁed dS.1/mutIN pREC-nﬂ
plasmid DNAs for their genetic diversity. The dS.1/mutIN VLPs do
not harbor gRNA, so we cannot estimate genetic diversity within
the patient-derived VLP preparations. We did compare the genetic
diversity within the VP pREC and subcloned dS.1/mutIN pREC by
PCR ampliﬁcation and NGS of the C2-V3 of Env. The topology of
Fig. 2 VPs and VLPs are genetically diverse preparations. Neighbor joining trees of nucleotide sequences were generated with MEGA6 and
visualized with FigTree 1.4.2 to highlight sequence heterogeneity. Phylogenetic trees were reconstructed for viral particles (red) and for virus
like particles (blue). VLP pREC_nﬂ DNAs were combined to generate Het_B_ACT-VEC
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the phylogenetic trees is similar for VP pREC-nﬂ and sub-cloned
dS.1/mutIN pREC-nﬂ for each patient (Fig. 2). On average, each VP
and VLP pREC_nﬂ contained 65 (range = 49–98) and 30.6 (range =
22–29) unique sequences, corresponding to an average of 0.006
(range = 0.00192–0.022) and 0.0178 (range = 0.0013–0.082) sub-
stitutions/nucleotide (Table S2).
VLPs are non-infectious, devoid of 5′LTR, and have reduced viral
RNA packaging
While inactivated (killed) whole VPs have been used to prevent a
wide range of viral diseases, the use of AT-2 inactivated, ultraviolet
(UV)-irradiated, whole HIV particles as a vaccine has been a
concern due to safety but has recently undergone a phase I
clinical trial evaluation showing no residual vaccine replication or
any evidence of vaccine viral genetic material.25 Given the
enhanced safety considerations in our preparation, it is important
to note that previous generations of the VPs have been tested in
mice, rabbit, and macaques with no adverse effects noted.
Furthermore, the new generation of VLPs are currently being
prepared for phase I clinical trials. Both the VP formulations and
the dS.1/mutIN VLPs were unable to infect and replicate in a
permissive luciferase expressing TZM-bl cell line. This contrasts
with B4, an infectious subtype B chimeric virus (Env from a primary
isolate placed into an NL4-3 backbone), which was readily able to
infect this highly susceptible cell line in a concentration-
dependent manner (Fig. 3c).
Both VPs and Het_B_ACT-VEC can stimulate antigen-speciﬁc
memory T-cell responses
The ﬁve volunteer-derived dS.1/mutIN pREC-nﬂ plasmid DNAs
were all combined to generate a highly heterogeneous and
polyvalent Het_B_ACT-VEC VLP preparation. This was used to
transfect 293T cells and produce Het_B_ACT-VEC VLP formula-
tions. We PCR ampliﬁed and sequenced the VP, dS.1/mutIN (VLP),
and Het_B_ACT-VEC pREC-nﬂ sequences using NGS. Phylogenetic
trees reveal a topology similar to a tree containing the population
of all other pREC-nﬂ as expected (Fig. 2).
To determine whether VP and Het_B_ACT-VEC were antigenic
and capable of stimulating antigen-speciﬁc T-cell recall responses,
we assayed the formulations in a monocyte-derived dendritic cell
(MDDC)–CD4+ T-cell co-culture assay using cells derived from HIV-
infected volunteers (Fig. 5a). Peripheral blood mononuclear cells
(PBMCs) from seven volunteers were puriﬁed by negative
selection to generate isolated, untouched CD4+ T cells with purity
>95% (Fig. S4a). Patient-derived MDDCs were grown by plastic
adherence and in the presence of interleukin (IL)-4 and
granulocyte macrophages colony-stimulating factor (GM-CSF) for
6 days. Resulting MDDCs were checked for phenotypic markers of
differentiation, such as HLA-DR, CD83, and CD209 (Fig. S4b).
MDDCs were pulsed overnight with VP5 or Het_B_ACT-VEC before
washing and co-culturing with autologous CD4+ T cells in a human
interferon (IFN)-γ ELISpot assay (Fig. 5a, b). As shown, the VP5 (**p
> 0.005) and the Het_B_ACT-VEC (*p > 0.05) were antigenic and
generated signiﬁcant numbers of spot-forming units (SFU)/106
CD4+ T cells when compared to the unstimulated MDDC-CD4+ T
cell co-cultures (Fig. 5b). No statistical difference in the generation
of SFU was observed between VP5 and the Het_B_ACT-VEC
formulation, thus demonstrating that the Het_B_ACT-VEC vaccine
construct is antigenic and can stimulate memory CD4 T-cell recall
responses in primary human cells. We further veriﬁed the ability of
Het_B_ACT-VEC and VPs to stimulate primary and secondary
immune responses using our MDDC–CD4 T-cell co-culture assay
and PBMCs from healthy donors using intracellular cytokine
staining ﬂow cytometry (Fig. S5a, b). In this instance, Het_B_ACT-
VEC was able to induce tumor necrosis factor (TNF)-α and IL-2
cytokine responses (average two-fold increase over media control)
with only a low-level increase in IFN-γ. The VPs tested, especially
VP 2, 4, and 5 were also capable of eliciting primary CD4 T-cell
responses with the magnitude greater than that seen with
Het_B_ACT-VEC. Again, no statistical difference in the generation
Fig. 3 Virus-like particle formulations are non-infectious due to
engineered RNA packaging defects and deletion of the HIV-1 5′LTR.
a RNA packaging knockdown in individual VLP formulations (VLP1-
4 + Het_B_ACT-VEC) were compared against near-full length viral
particles (VP) formulations lacking mutations in the RNA packaging
sequence by ﬁrst isolating viral RNA and then by qRT-PCR using a
gag primer set. b The VLP encoding pREC_nﬂ DNAs were evaluated
for the presence/absence of HIV-1 gag, env, and 5′LTR by PCR and
gel electrophoresis using gag, env, and 5′LTR—gag primer sets.
Samples derived from the same experiment and gels were
processed in parallel. c VP (-dS.1/mutIN) and VLP (+dS.1/mutIN)
formulations were compared to infectious B4 virus for infectivity
using luciferase TZM-bl cells. Infectivity results are represented by
relative light units (RLUs). Luciferase quantiﬁcation was done in a
Synergy H4 Hybrid microplate reader using 50 μl of luciferase assay
reagent
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of cytokine responses was observed between the different VPs
and the Het_B_ACT-VEC formulation was detected (Fig. S5b).
In addition to VP5 and Het_B_ACT-VEC abilities to stimulate CD4
T cells, the formulations were evaluated for their abilities to
stimulate exocytosis of Granzyme B (GzB), a potent proapoptotic
granzyme associated with cytotoxic functioning. This was done
using VP5 and Het_B_ACT-VEC pulsed PBMCs using ELISpot.
Shown are the GzB cytotoxic response of two HIV+ volunteers
upon stimulation with VP5 and Het_B_ACT-VEC (Fig. 5c).
Volunteers 583 and 993 had a mean 25 and 35 GzB+ SFU/106
PBMCs when stimulated with the media control (assay cutoff = 50
SFU/106) while VP5 and Het_B_ACT-VEC had 161.7 and 127.5 GzB+
SFU/106 and 113.3 and 105 GzB+ SFU/106, respectively.
DISCUSSION
Over the past few centuries, empirically derived vaccines have
slowly been replaced by rationally designed vaccines. During this
time, killed/attenuated vaccines have demonstrated huge success
in providing protection from a range of communicable diseases.
However, safety concerns regarding insufﬁcient attenuation and
inactivation processes still remain. In the context of HIV-1 vaccines,
attenuated versions of HIV raise serious ethical concerns due to
the fear of reversion to virulence following vaccination or the
potential for recombination with resident HIV following
therapeutic vaccination.26,27 Methods to inactivate HIV-1, such as
AT-2 treatment and UV irradiation, may result in a safe vaccine,25
but these conditions may also alter antigenicity and could affect
the conformation of viral glycoproteins. As such, research into
safer and stronger alternatives to the killed/attenuated HIV-1 has
gained signiﬁcant traction. This study describes the development
of non-infectious VPs derived from infected patients and their
reformulation into VLPs that are then used to produce a
heterogeneous VLP formulation called Het_B_ACT-VEC. The
Het_B_ACT-VEC is currently being tested as both a prophylactic
and therapeutic vaccine. In the latter case, the Het_B_ACT-VEC is
being used as a latency reversal agent as part of the “Shock and
Kill Strategy”, the aim being to trigger proviral transcription and
the elimination of infected cells.15,28
Our ﬁrst prototype of this HIV-1 vector, termed VP, was derived
from the pREC-nﬂ construct.17 HIV-1 mRNA is transcribed off pREC-
nﬂ (near full length) from a minimal cytomegalovirus promoter,
deleting the 5′LTR promoter/enhancer region such that transcrip-
tion is initiated at the ﬁrst nucleotide of the primer binding
sequence. Aside from deleting the Tat-transactivating response
element found within the 5′LTR, all other RNA regulatory
sequences remain intact such that all HIV-1 mRNA species (un-
spliced, singly spliced, and multiply spliced) are expressed, the full
HIV-1 proteome translated, and VPs assembled and released from
these cells.17 We have previously shown that the nﬂ VPs released
Fig. 4 pREC-nﬂ derived VP and VLPs share are morphologically similar to wild-type virus. a 293T cells were transfected with pREC_nﬂ plasmids
encoding VPs (−dS.1/mutIN) and VLPs (+dS.1/mutIN). Samples were ﬁxed and embedded in Resin-Araldite Embed 812 before imaging via
transmission electron microscopy (Philips CM10 TEM). White scale bar is 100 nm. b Puriﬁed VP and VLP preparations were analyzed by
dynamic light scattering at 25 °C using a Malvern Zetasizer Nano (Malvern Instruments Ltd). The intensity of the laser light scattered by the
sample preparations was detected at 90° to the incidence beam. Data were analyzed using the Malvern software. c Puriﬁed VPs and VLPs were
assessed for evidence of protease cleavage of the gag-pol polyprotein by anti-p17 western blot
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from this system cannot initiate reverse transcription (i.e., no
minus strong stop DNA synthesis), are non-infectious, and cannot
be complemented by superinfection with a wild-type HIV-1.17
Despite rendering the lentiviral VPs non-infectious, the pre-
sence of nﬂ viral genomic RNA within vaccine formulations still
poses a concern in vaccine development. Therefore, we intro-
duced extensive mutations into the stem loop 1 (dS.1) of the RNA
packaging element that strongly reduced genomic RNA encapsi-
dation in VLPs, paralleling observations made by Clever and
Parslow in 1998 with a laboratory-adapted HIV-1 clone.21 In our
studies, the dS.1 mutations coupled with the deletion of the 5′LTR
did not impact p24 content or RT activity in the VLPs but depleted
gRNA encapsidation and resulted in non-infectious particles.
Finally, during the ampliﬁcation of the patient-derived HIV-1
genomes, we introduced a 262RRK>AAH mutation into the active
site of HIV-1 IN. In contrast to the nﬂ VPs, the dS.1/mutIN VLPs and
Het_B_ACT-VEC (with Δ5′LTR/mutIN/dS.1) harbored a defective IN
incapable of the dinucleotide cleavage, which ensured the
nulliﬁcation of viral infectivity.
In the absence of Gag-gRNA complexes, Gag can still
oligomerize to produce VLPs of varying size and structure,
whereas the inclusion of the full proteome (including the Env
glycoprotein) appears to generate more uniform VPs, which was
evident from our electron microscopic images on all formulations.
While HIV VP formation is dependent only on Gag production, Env
is required for virus entry into host cells and could elicit protective
antibody responses. We propose that these fully processed wild-
type VPs may be highly antigenic and could induce neutralizing
responses, considering the viral proteins should be in a native
“wild-type” structure, and can even undergo conformational
changes related to viral entry, core deposition, and dissolution
in the cell cytoplasm. However, it should be pointed out that not
all VPs or VLPs will carry intact, native-like trimers nor will all the
expressed Env become appropriately cleaved, and a fraction
would certainly exist as monomers, dimers, and gp41 stumps.29
The development of a neutralizing antibody response would of
course be highly beneﬁcial for an anti-HIV prophylactic vaccine,
enabling the neutralization of transmitted founder viruses at the
earliest time points following virus exposure; however, anti-HIV
antibody and neutralizing antibody responses would also be
beneﬁcial for therapeutic vaccines. In the latter case, it is
envisaged that either an elicited neutralizing or antibody-
Fig. 5 Puriﬁed VP and Het_B_ACT-VEC formulations are capable of human CD4+ T-cell activation in vitro. a PBMC from fully consented HIV+
volunteers (n= 7) were used to generate monocyte-derived dendritic cells (MDDCs), which were pulsed overnight with Het_B_ACT-VEC VLP or
VP5 and co-incubated with autologous puriﬁed CD4+ T cells. b Cells were cultured overnight in a human IFN-γ ELISpot assay and the IFN-γ
spot-forming units were enumerated per 106 CD4+ T cell using the ImmunoSpot S5 UV Analyzer and ImmunoSpot 5.0.9 software. Results
shown are mean SFU/106 CD4+ T cells (+/− SEM). c HIV-infected PBMCs from two randomly selected donors are shown, representing the
ability of ACT-VEC and VP5 to elicit Granzyme B (GzB) cytotoxic responses using overnight culture in a GzB ELISpot. In all cases, an assay cutoff
of 50 SFU/106 cells was used. Mann–Whitney non-parametric U-test was used to determine inter-sample statistical signiﬁcance. We considered
p> 0.05 to be statistically signiﬁcant. Graphics depicted in this ﬁgure were generated by the authors
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dependent cell cytotoxicity response could aid therapeutic
vaccination by blocking de novo infections occurring in response
to latency reversal (Shock) and also in the eradication (Kill) of
virally infected cells.15,28
While B-cell immunogens are important in providing protection
through the generation of neutralizing and non-neutralizing
antibody production, T-cell immune responses play an important
role in controlling viral loads and priming B-cell responses.
Therefore, it stands to reason that an efﬁcacious prophylactic or
therapeutic vaccine should elicit both T- and B-cell responses to
either prevent infection at the level of the mucosa or eliminate
infection through sterilizing immunity. Hence, it is important that
our formulations can elicit both CD4 T helper cell and GzB
cytotoxic functions in PBMC. Until such time that a broadly
neutralizing antibody response can be successfully elicited
through vaccination, anti-HIV cytotoxic responses could be highly
beneﬁcial in both prophylactic and therapeutic vaccine settings,
i.e., in the elimination of infectious foci during the narrow
“window of opportunity” and in controlling/eradicating produc-
tively infected cells within HIV-infected individuals, respec-
tively.15,30,31 Attenuated viral vectors (e.g., ALVAC or Ad5)
expressing more conserved HIV-1 proteins (e.g., Gag) or protein
motifs (e.g., repeated strings of immunodominant/conserved HIV
peptides) have been tested as CTL-based vaccines with moderate
success in animal models but mostly failed in human clinical
trials.32 Although many factors led to these vaccine failures, CTL
escape mutations rapidly appear in the infecting HIV during both
preventative and therapeutic vaccine trials. These studies, as well
as the failure of most humoral based vaccines, have prompted us
to construct and test a heterogenous HIV vaccine, which consist of
“dead” HIV-1 particles lacking undesirably foreign vector
components.
Our yeast recombination system produces vectors that harbor
the same HIV-1 quasi-species diversity found within patient
samples. By combining the subtype B HIV quasi-species from ﬁve
patients, we have generated a heterogenous dS.1/mutIN VLP
(termed Het_B_ACT-VEC). To further develop our therapeutic and
cure-based vaccine strategies, we screen patients for subtype
infection and then employ the respective ACT-VEC, currently
being tested in ex vivo experiments with the aim of selecting the
most effective vaccine modalities for use in a future clinical trial.
We are currently testing different heterogenous forms of this
dS.1/mutIN VLP as (1) anti-HIV therapeutic/cure strategies,
designed to elicit T-cell responses for activating the latent HIV
pool and for reducing viral loads, and (2) a prophylactic vaccine
designed to augment antiviral antibody titres and to harness CD4+
T-cell responses. The DNA vector pREC-nﬂ is also being tested as a
DNA vaccine administered by intramuscular electroporation in
animal models and may be very effective in combination with the
VLP and Het_B_ACT-VEC for prime-boost therapeutic and
prophylactic vaccinations. As described in a recent study,
Het_B_ACT-VEC may also lead to latency reversal and elimination
of much of the HIV-1 reservoir that remains in these HIV-infected
patients receiving cART. In conclusion, our dS.1/mutIN VLP
formulations appear safe in vitro, and we anticipate that VLPs
and Het_B_ACT-VEC formulations will be safe for use in humans;
however, this will need to be conﬁrmed in future planned non-
human primate studies and human clinical trials. The VLPs and
Het_B_ACT-VEC also present the entire HIV proteome in the
correct conformation, reﬂect the HIV-1 genetic diversity within
infected individuals and, consequently, have wide range of uses.
MATERIALS AND METHODS
Ethics statement
For antigenicity studies, either HIV-positive volunteers were recruited from
the HIV adult clinical St Mary's Hospital (Imperial College NHS trust),
through a protocol approved by the NHS Health Research Authority
(protocol number: 14SM1988) or healthy volunteer PBMCs were purchased
from Canadian Blood Services under institutional REB approval (no:
106951). Written informed consent was provided by all HIV+study
participants prior to the study start. PBMCs from HIV+ volunteers used in
these studies had suppression of viremia to <50 copies HIV-1 RNA/ml for
>6 months on ART. For VP, VLP, and Het_B_ACT-VEC production, HIV+ sera
from ﬁve consenting HIV+ adult volunteers were obtained under internal
review board approval (AIDS125) at Case Western Reserve University,
(CWRU, USA). Methods were performed in accordance with relevant
regulations and guidelines.
VP and VLP vaccine production
All formulations were cloned using a similar protocol to that previously
described and schematically depicted in Figure S1.16–18 Brieﬂy, sera-
derived viral RNA was isolated using a viral RNA Isolation Kit (Qiagen, USA)
and reverse transcribed to cDNA (Agilent Technologies, USA) using two
primers to generate a 5′ (5020R) and 3′ (1.R3.B3.R) fragment encompassing
the entire HIV-1 genome. The two overlapping cDNA fragments were then
PCR ampliﬁed in a nested PCR protocol using 5′ and 3′ primer pairs
described in Table S1. The two fragments were then transfected into S.
cerevisiae in a 1:1 ratio with 2 μg SacII linearized plasmid, pRECΔgag-U3/
URA3. Yeast colonies were selected on complete medium lacking leucine
(C−Leu) plates supplemented with ﬂuoroorotic acid (FOA). The resulting
plasmid vectors were isolated by an in-house yeast miniprep and used to
transform bacteria to amplify the DNA plasmid for puriﬁcation as described
previously. It is important to note that the PCR products harbored the
ampliﬁed patient quasi-species, and as such, >100 yeast colonies were
removed from Leu−/FOA plates for bulk plasmid puriﬁcation and eventual
reconstitution of sample quasi-species. The resulting plasmid constructs
were isolated and then used to transfect 293T cells (NIH AIDS Reagent
Program) with Fugene 6 transfection reagent (Promega, USA) to produce
viral VP and VLPs. This procedure of highly efﬁcient yeast-based
recombination/cloning followed by 293T transfections is believed to
preserve the HIV-1 quasi-species population better than a similar approach
using bacterial-restriction enzyme cloning. VP and VLPs were then puriﬁed
by centrifugation through 100 KDa MWCO centrifuge tubes (Amicon, USA)
and re-suspended in sterile phosphate-buffered saline (PBS).
Vaccine quantitation and protein production assessment
VP and VLP production from 293T cells was monitored for transfection
efﬁciency by p24 ELISA assay, provided under an MTA by the AIDS Vaccine
Program, National Cancer Institute (NCI) at Frederick, MD, USA. A
radioactive RT assay was also used to measure VP and VLP levels in cell-
free supernatants as described previously.18 Viral proteins in formulations
were also analyzed by western blot using NuPAGE Novex 3–8%
Tris–Acetate Protein Gels (Thermo-Fischer Scientiﬁc) and a 1:100 dilution
of heat-inactivated serum derived from SHIV-infected macaques, before
addition of a 1:2000 dilution of goat anti-monkey IgG: horseradish
peroxidase (HRP) (Bio-Rad). Samples were then developed with 3,3′-
diaminobenzidine (DAB) SK-4100 (Vector Laboratories). For anti-p17
western blots, a 10–20% Novex Tris-Glycine Mini-Gel (Thermo Fisher, Ca)
was used. Membranes were blocked and then stained for 2 h with 1:5000
dilution of polyclonal rabbit anti-p17 antibodies (NIH AIDS Reagent
Program), The membrane was then incubated with goat anti-rabbit HRP
(Abcam) at 1:2000 concentration and developed using DAB Liquid
Substrate (Vector Laboratories).
Size estimation of vaccine particles
VP and VLP size and particle distribution were measured using DLS with a
Malvern Zeta-Sizer Nano (Malvern Instruments Ltd) at 25 °C. Brieﬂy, puriﬁed
VP and VLPs were diluted into 1ml PBS and placed into 4.5 ml polystyrene
analysis cuvettes (Fisher Scientiﬁc, CA). The intensity of laser light scattered
by the sample preparations was measured at 173° to the incident beam.
The data were analyzed using the proprietary Malvern software, DTS (Nano
Version 5.0), supplied with the machine. The size distribution and the
polydispersity were measured using non-invasive back scatter.
NGS analysis of vaccine formulations
The C2–V3–C3 region of envelope was ampliﬁed by an external-nested
PCR ampliﬁcation using the primers forward EnvB and reverse ED14
(external) and forward E80 and reverse E125 (nested) using PCR cycle
conditions as described previously.33 To prepare the amplicon library for
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454 sequencing, fusion primers including the Roche 454 titanium key
sequence and multiplex identiﬁer (MID) sequence for forward and reverse
primers followed by the template speciﬁc forward (E110) and reverse
(E125) sequences were generated. The nested products were re-ampliﬁed
with barcoded MIDs. The PCR products were run on a 1% agarose gel to
verify the 406 bp size and then puriﬁed with the Agencourt AMPure XP
bead system with a bead: DNA ratio of 0.7:1 according to the Roche
manual. Following puriﬁcation, PCR ampliﬁed sample libraries were
quantiﬁed using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen),
diluted, and pooled together at 106 molecules/µl for pyrosequencing as
per Roche 454 instructions.
Following emulsion PCR (emPCR) at a ratio of 0.5 molecules of sample
library per bead, 5 × 105 enriched beads were loaded onto the titanium
picotiter plate, which was run on the Roche 454 GS Junior instrument. Raw
sequence data were extracted by the MID tag using a custom analysis
pipeline. The 454 amplicon adapters were trimmed and sequences of
<200 bp were discarded. Sequences were edited using BioEdit v7.2.5 and
aligned using maximum likelihood methods (MUSCLE).34,35 Neighbor
joining and maximum likelihood trees were constructed with SEAVIEW 4
and visualized with FigTree 1.4.2. Kimura genetic distance analysis within
each sample were calculated using MEGA 6 and is expressed as
substitutions per nucleotide (s/nt).36,37 Any genetic variants with
hypermutations at homopolymeric tracts and/or appearing less than three
times were removed from the analyses.
Isolation of resting CD4+ T lymphocytes and MDDCs
CD4+ T lymphocytes were enriched from PBMCs by negative depletion
(Miltenyi Biotec) using magnetic microbeads. To obtain immature DCs,
PBMC were plastic adhered at 37 °C for 2 h. Adhering monocytes were
washed to remove non-adherent cells and then differentiated into MDDCs
by culturing in complete RPMI (10% fetal calf serum (FCS)+2mM L-
Glutamine) supplemented with GM-CSF and IL-4 (1000 and 500 U/ml,
respectively) for 6 days.
TZM-bl infectivity assay
The infectivity of VP and VLP preparations were estimated in TZM-bl cells
(NIH AIDS Reagent Program) by luciferase quantitation of cell lysates
(Promega, Madison, WI). Brieﬂy, TZM-bl cells were seeded at 1 × 104/well
prior to addition of 50 ng/ml (based on p24) VPs and VLP formulations.
After 48 h incubation, cells were washed with PBS and lysed with 100 μl of
lysis reagent. A 50 μl volume was used for luciferase quantiﬁcation in a
Synergy H4 Hybrid microplate reader (BioTek Instruments, Inc., Burlington,
VT) using 50 μl of luciferase reagent. The extent of luciferase expression
was recorded in relative light units.
Transmission electron microscopy
VP- and VLP-transfected 293T cells were collected in 15ml tubes before
pelleting at 1250 rpm for 10min. Cells were washed with sodium
cacodylate (pH 6.5) before re-suspending in 500 μl of 2.5% glutaraldehyde
in sodium cacodylate. Supernatants were removed, and pelleted cells were
re-suspended in 1% osmium tetroxide in sodium cacodylate for 1 h with
shaking. Samples were then centrifuged and washed with deionized water.
Dehydration was performed by re-suspending samples in 1 ml of
increasing concentrations of acetone (30%, 50%, 70%, 90%, 95%, 100%)
for 10min each. Serial resuspensions with acetone: TEM Resin-Araldite
EMbed 812 (2:1, 1:1, 1:2, whole TEM resin) followed, until all acetone was
replaced by resin. Samples were then baked at 60 °C for 48 h and resin-
embedded samples were cut into 70 nm wide sections using an UltraCut
UltraMicrotome (Sorvall) before copper mesh mounting and staining with
Uranyl Acetate. Samples were dried and stained with Lead Citrate before
washing thoroughly with sterile water. Samples were air dried and then
imaged on a Philips CM10 TEM.
Antigenicity assays
Human IFN-γ and GzB enzyme-linked immunosorbent spot (ELISpot)
assays (Mabtech, USA), as well as intracellular cytokine staining ﬂow
cytometry were carried out on MDDC–CD4+ T-cell co-cultures and PBMCs.
ELISpot were carried out as per the manufacturer's instructions. Brieﬂy anti-
IFN-γ precoated plates or anti-GzB-coated plates were washed with sterile
PBS and then blocked for 30min using complete RPMI. Plates were again
washed before addition of 1 × 106 cells/ml CD4+ T cell or 106 lymphocytes
from PBMCs. MDDC-stimulated CD4+ T cells and PBMCs were then
incubated for 16 h to assess the number of HIV-speciﬁc CD4+ T cells and
GzB-secreting cytotoxic cells. Unstimulated and 5 μg/ml phytohemagglu-
tinin (PHA)/ionomycin (Iono) (Sigma, USA)-stimulated cells served as
controls. To detect spots, biotinylated anti-IFN-γ or anti-GzB antibody was
added at 1 μg/ml for 2 h before washing and incubating with
streptavidin–HRP for 1 h. Plates were washed and 100 μl/well of TMB
substrate was added. SFU were enumerated per 106 cells using the
ImmunoSpot S5 UV Analyzer (Cellular Technology Ltd., Cleveland, OH) and
ImmunoSpot 5.0.9 software. Results are mean values (+/− SEM). For ﬂow
cytometric analysis of T-cell activation, CD4+ T cells were incubated for 2 h
with ACT-VEC or VP-pulsed MDDCs before 4 h incubation with monensin.
Samples were washed using FACs buffer (2.5% FCS in PBS) and surface
stained with anti-CD3 (BD Bioscience, SK7) and anti-CD4 (Biolegend, RPA-
T4) antibody. Samples were washed again before permeabilizing using a
BD FACS Fix Perm Kit (Becton Dickinson, USA). The samples were then
incubated with anti-IFN-γ (Biolegend, 45.B3), anti-TNF-α (eBioscience,
Mab11), and anti-IL-2 (Biolegend, MQ1-17H12) antibody in FACS perm
wash solution before washing in FACs buffer and then ﬁxing in 1.5%
methanol-free paraformaldehyde (Polysciences, USA) in PBS. Samples were
analyzed on a FACS LSR II instrument with the FACS Diva software. Data
analysis was performed with FlowJo (Treestar Inc., OR, USA).
Statistics
Mann–Whitney non-parametric U-test was used to determine inter sample
statistical signiﬁcance where indicated. We considered p > 0.05 to be
statistically signiﬁcant. Based on previous studies, a group size of seven (n
= 3) was required to be provide sufﬁcient power in the ELISpot studies. As
samples from all patients were handled in the same way, there was no
randomization or blinding.
Data availability
Supporting data for this study are available from the corresponding author
upon reasonable request.
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